- Home
- NXGL vs DCOY Comparison
NXGL vs DCOY Comparison
Compare NXGL & DCOY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NXGL | DCOY |
|---|---|---|
| Founded | 1997 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.9M | 3.2M |
| IPO Year | 2019 | 2014 |
Fundamental Metrics
Financial Performance| Metric | NXGL | DCOY |
|---|---|---|
| Price | $0.17 | $1.58 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 281.0K | ★ 4.1M |
| Earning Date | 11-10-2026 | 11-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 24.00 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $11,421,000.00 | N/A |
| Revenue This Year | $38.23 | N/A |
| Revenue Next Year | $53.72 | $20.42 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 31.46 | N/A |
| 52 Week Low | $0.16 | $0.53 |
| 52 Week High | $2.89 | $13.51 |
Technical Indicators
Market Signals| Indicator | NXGL | DCOY |
|---|---|---|
| Relative Strength Index (RSI) | 27.36 | 29.82 |
| Support Level | $0.16 | $0.61 |
| Resistance Level | $0.59 | $3.29 |
| Average True Range (ATR) | 0.03 | 0.68 |
| MACD | -0.00 | -0.10 |
| Stochastic Oscillator | 13.77 | 0.17 |
Price Performance
Historical ComparisonAbout NXGL NexGel Inc
NexGel Inc manufactures high water content, electron beam cross-linked, aqueous polymer hydrogels, or gels, used for wound care, medical diagnostics, transdermal drug delivery, and cosmetics. The company specializes in custom gels by capitalizing on proprietary manufacturing technologies. The gels and consumer products are manufactured using proprietary and non-proprietary mixing, coating and cross-linking technologies.
About DCOY Decoy Therapeutics Inc. Common Stock
Decoy Therapeutics Inc is a pre-clinical stage biotechnology company focused on advancing its pipeline of peptide conjugate therapeutics engineered through its proprietary IMP3ACT platform. The IMP3ACT platform represents a paradigm shift in peptide conjugate drug discovery and manufacturing, leveraging machine learning (ML) and artificial intelligence (AI" tools alongside high-speed synthesis techniques to rapidly engineer, optimize and manufacture peptide conjugates that target serious unmet medical needs. The company manages its business in one operating segment, focused on the discovery and development therapeutics for patients with high, unmet medical needs. Its pipeline programs include: Pan-Coronavirus; and Tripledemic.